Bronnen:
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-74. doi: 10.1016/j.cell.2011.02.013. Review.,Eidelman E, Twum-Ampofo J, Ansari J, Siddiqui MM. The Metabolic Phenotype of Prostate Cancer. Front Oncol. 201719;7:131. doi: 10.3389/fonc.2017.00131. eCollection 2017.,Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond). 2012;122:253-70. doi: 10.1042/CS20110386. Review.,Whitburn J, Edwards CM, Sooriakumaran P. Metformin and Prostate Cancer: a New Role for an Old Drug. Curr Urol Rep. 2017;18:46. doi: 10.1007/s11934-017-0693-8.,Sayyid RK, Fleshner NE. Potential role for metformin in urologic oncology. Investig Clin Urol. 2016;57:157-64. doi: 10.4111/icu.2016.57.3.157. Epub 2016 May 10.,Xiao Y, Zheng L, Mei Z, Xu C, Liu C, Chu X, Hao B. The impact of metformin use on survival in prostate cancer: a systematic review and meta-analysis. Oncotarget. 2017;8:100449-100458. doi: 10.18632/oncotarget.22117. eCollection 2017 Nov 21.,Rothermundt C, Hayoz S, Templeton AJ3-, Winterhalder R, Strebel RT, Bärtschi D, Pollak M, Lui L, Endt K, Schiess R, Rüschoff JH, Cathomas R, Gillessen S. Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09). Eur Urol. 2014;66:468-74. doi: 10.1016/j.eururo.2013.12.057. Epub 2014 Jan 4.,Gillessen S, Gilson C, James N, Adler A, Sydes MR, Clarke N; STAMPEDE Trial Management Group. Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform. Eur Urol. 2016;70:906-908. doi: 10.1016/j.eururo.2016.07.015. Epub 2016 Jul 19.,The Metformin Active Surveillance Trial (MAST) Study (MAST). https://clinicaltrials.gov/ct2/show/NCT01864096 (consulted 1/11/2017)